Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report.
Anat FisherJason D KimColin R DormuthPublished in: Pharmacoepidemiology and drug safety (2020)
An increase in visits to physicians was expected but not detected in the first three months of the Biosimilars Initiative. The impacts of the policy will continue to be monitored.